Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically.
Researched for
Senolysis (selective elimination of senescent cells) in mouse modelsAnti-aging concept (theoretical + preclinical)Renal fibrosis and tissue homeostasis in animal models
Official status
US: Research only
No FDA approval. Use exclusively in academic and industrial research; black-market distribution exists in bio-hacking communities.
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 2 tiers
Animal model
2
Theoretical
1
03
What the studies show
Animal model
Maus
Baar MP. et al. 2017
Selective elimination of senescent cells in multiple tissues of old and chemotherapy-treated mice documented
What does NOT follow: Original finding of the Demaria group (Cell 2017). Later replication attempts by other labs have produced mixed results; selectivity for senescent cells is not unchallenged.
Animal model
Maus
Baar MP. et al. 2017
Improvement of marker endpoints (hair growth, renal function, running endurance) reported in the original mouse study after multi-week treatment
What does NOT follow: Animal model endpoints; translation to humans is not established. No controlled human trials.
Theoretical
—
No published human studies on efficacy or safety
What does NOT follow: Human use is exclusively self-experiment in bio-hacking circles; without controlled phase-1 safety data, an assessment of benefit or risk is impossible.
04
Where studies disagree
Open question
Can FOXO4-DRI's selectivity for senescent cells be independently replicated?
POSITION A
Demaria et al. 2017 showed clean selectivity in multiple mouse models.
POSITION B
Later replication attempts by other labs produced heterogeneous results; some report off-target effects.
CURRENT STATE · Senolysis research overall is young and methodologically still standardising. FOXO4-DRI remains an interesting basic-research tool; a therapeutic position for humans is not established.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.5 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Intravenous
In mouse models administered intravenously in multi-day cycles.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Animal model
Acute toxicity in animal models appears low
Animal study observation; safety profile in humans practically unknown. Broad p53 activation theoretically carries oncogenic and immunological risk.
in Studien dokumentiert
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Early preclinical stage, no human safety profile
The only published efficacy study is the Demaria 2017 publication in Cell. Clinical phase-1 data in humans are not publicly available. Black-market use without pharmacological supervision carries uncalculated risks.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In longevity communities FOXO4-DRI is occasionally described as 'the first senolytic peptide drug'.
occasional in bio-hacking forums, less widespread than Epitalon
Not supported by studies: This claim is technically correct in terms of preclinical research but ignores that it is a substance validated exclusively in animal experiments without a phase-1 human study. Risk profile in humans is not established.
11
Legal status by country
Country
Status
Note
Checked
United States
Research only
No FDA approval. Use exclusively in academic and industrial research; black-market distribution exists in bio-hacking communities.
2026-05-22
Germany
Research only
No EMA approval. Not marketable as a medicine.
2026-05-22
NL
Research only
Research activity concentrates at the ERIBA institute in Groningen (Demaria group).
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.